After concluding 2024 with strong sales growth, financial strength, and significant pipeline progress, Zai Lab Limited (ZLAB) is now focused on achieving substantial topline growth, with a goal of reaching $2 billion in revenue by 2028.
This commercial-stage, global biopharmaceutical company with a significant presence in both Greater China and the United States has seven marketed products that have been successfully launched in one or more territories across Greater China.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com